Consider TLR5 for new therapeutic development against COVID-19

被引：47

作者：

Chakraborty, Chiranjib ^{[1
,2
]}

Sharma, Ashish Ranjan ^{[2
]}

Bhattacharya, Manojit ^{[2
]}

Sharma, Garima ^{[3
]}

Lee, Sang-Soo ^{[2
]}

Agoramoorthy, Govindasamy ^{[4
]}

机构：

[1] Adamas Univ, Sch Life Sci & Biotechnol, Dept Biotechnol, Barasat Barrackpore Rd, Kolkata 700126, W Bengal, India

[2] Hallym Univ, Inst Skeletal Ageing & Orthoped Surg, Chuncheon Sacred Heart Hosp, Chuncheon Si, Gangwon Do, South Korea

[3] Kangwon Natl Univ, Coll Pharm, Neuropsychopharmacol & Toxicol Program, Chunchon, South Korea

[4] Tajen Univ, Coll Pharm & Hlth Care, Pingtung 907, Taiwan

来源：

JOURNAL OF MEDICAL VIROLOGY | 2020年 / 92卷 / 11期

关键词：

COVID-19; therapeutic development; TLR5; INNATE;

D O I：

10.1002/jmv.25997

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

引用

页码：2314 / 2315

页数：2

共 13 条

[1] Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach
Bhattacharya, Manojit
Sharma, Ashish R.
Patra, Prasanta
Ghosh, Pratik
Sharma, Garima
Patra, Bidhan C.
Lee, Sang-Soo
Chakraborty, Chiranjib
[J]. JOURNAL OF MEDICAL VIROLOGY, 2020, 92 (06) : 618 - 631
[2] Frontline Science: Nasal epithelial GM-CSF contributes to TLR5-mediated modulation of airway dendritic cells and subsequent IgA response
Cao, Yuan
Zhang, Ejuan
Yang, Jingyi
Yang, Yi
Yu, Jie
Xiao, Yang
Li, Wei
Zhou, Dihan
Li, Yaoming
Zhao, Bali
Yan, Hu
Lu, Mengji
Zhong, Maohua
Yan, Huimin
[J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2017, 102 (03) : 575 - 587
[3] Utilizing a TLR5-Adjuvanted Cytomegalovirus as a Lentiviral Vaccine in the Nonhuman Primate Model for AIDS
Deere, Jesse D.
Chang, W. L. William
Castillo, Luis D.
Schmidt, Kim A.
Kieu, Hung T.
Renzette, Nicholas
Kowalik, Timothy
Barthold, Stephen W.
Shacklett, Barbara L.
Barry, Peter A.
Sparger, Ellen E.
[J]. PLOS ONE, 2016, 11 (05):
[4] Toll-like receptor 5 agonist flagellin reduces influenza A virus replication independently of type I interferon and interleukin 22 and improves antiviral efficacy of oseltamivir
Georgel, Anne-France
Cayet, Delphine
Pizzorno, Andres
Rosa-Calatrava, Manuel
Paget, Christophe
Sencio, Valentin
Dubuisson, Jean
Trottein, Francois
Sirard, Jean-Claude
Carnoy, Christophe
[J]. ANTIVIRAL RESEARCH, 2019, 168 : 28 - 35
[5] Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease
Golonka, Rachel M.
Saha, Piu
Yeoh, Beng San
Chattopadhyay, Saurabh
Gewirtz, Andrew T.
Joe, Bina
Vijay-Kumar, Matam
[J]. PHYSIOLOGICAL GENOMICS, 2020, 52 (05) : 217 - 221
[6] Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development
Kim, Eun
Erdos, Geza
Huang, Shaohua
Kenniston, Thomas W.
Balmert, Stephen C.
Carey, Cara Donahue
Raj, V. Stalin
Epperly, Michael W.
Klimstra, William B.
Haagmans, Bart L.
Korkmaz, Emrullah
Falo, Louis D., Jr.
Gambotto, Andrea
[J]. EBIOMEDICINE, 2020, 55
[7] A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity
McDonald, William F.
Huleatt, James W.
Foellmer, Harald G.
Hewitt, Duane
Tang, Jie
Desai, Priyanka
Price, Albert
Jacobs, Andrea
Takahashi, Virginia N.
Huang, Yan
Nakaar, Valerian
Alexopoulou, Lena
Fikrig, Erol
Powell, T. J.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2007, 195 (11) : 1607 - 1617
[8] Mehta P., 2020, LANCET, V6736, P19
[9] TLR agonists as modulators of the innate immune response and their potential as agents against infectious disease
Mifsud, Edin J.
Tan, Amabel C. L.
Jackson, David C.
[J]. FRONTIERS IN IMMUNOLOGY, 2014, 5 : 1 - 10
[10] Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China
Qin, Chuan
Zhou, Luoqi
Hu, Ziwei
Zhang, Shuoqi
Yang, Sheng
Tao, Yu
Xie, Cuihong
Ma, Ke
Shang, Ke
Wang, Wei
Tian, Dai-Shi
[J]. CLINICAL INFECTIOUS DISEASES, 2020, 71 (15) : 762 - 768

← 1 2 →